<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02001363</url>
  </required_header>
  <id_info>
    <org_study_id>S2013-099-01</org_study_id>
    <secondary_id>ChinaPLAGH</secondary_id>
    <nct_id>NCT02001363</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Glucagonlike Peptide-1 to Treat Reperfusion Injury</brief_title>
  <official_title>Protective Effect of Glucagonlike Peptide-1 on Reperfusion Injury in Patients With Acute Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chen Wei Ren, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese PLA General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators planned to research the cardioprotective effects of intravenous liraglutide
      on reperfusion injury.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acute myocardial infarction is a major cause of mortality and morbidity. Primary percutaneous
      coronary intervention (pPCI) is currently the most effective treatment strategy in acute
      myocardial infarction. However, a sizable number of patients fail to restore optimal
      myocardial reperfusion, mostly because of the 'no-reflow' phenomenon. Glucagon-like peptide-1
      (GLP-1) is an incretin hormone that regulates plasma glucose, and recently GLP-1 analogues
      have been introduced for the treatment of type-2 diabetes. In experimental studies, GLP-1 or
      its analogues protect against reperfusion injury-induced cell death. Exenatide reduces
      reperfusion injury in patients with ST-segment elevation myocardial infarction.
      Liraglutide(GLP-1) is safe and effective to reduce weight,serum lipid levels and blood
      pressure. Liraglutide can reduce cardiac rupture (12 of 60 versus 46 of 60; P=0.0001) and
      infarct size (21±2% versus 29±3%, P=0.02) and improved cardiac output (12.4±0.6 versus
      9.7±0.6 ml/min; P=0.002) in normal and diabetic mice. The investigators planned to research
      the cardioprotective effects of intravenous liraglutide administered prior to reperfusion and
      continued after restoration of coronary blood flow in patients with STEMI undergoing pPCI.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">March 2016</completion_date>
  <primary_completion_date type="Anticipated">March 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the salvage index measured by cardiac magnetic resonance</measure>
    <time_frame>3 months after primary percutaneous coronary intervention</time_frame>
    <description>The primary endpoint was the salvage index measured by cardiac magnetic resonance after 3 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>major adverse cardiovascular events (MACE) after 3 months</measure>
    <time_frame>3 months after Primary percutaneous coronary intervention</time_frame>
    <description>major adverse cardiovascular events (MACE) after 3 months: recurrent myocardial infarction, recurrent angina, revascularization, heart failure, cardiac death.
treatment-emergent adverse events (TEAEs): hypoglycemia, nausea, acute pancreatitis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>final infarct size after 3 months</measure>
    <time_frame>3 months after Primary percutaneous coronary intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the levels of high-sensitivity C-reactive protein (hsCRP)</measure>
    <time_frame>3 months after Primary percutaneous coronary intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>nitric oxide (NO) levels</measure>
    <time_frame>3 months after Primary percutaneous coronary intervention</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>liraglutide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>drug: liraglutide (Novo Nordisk, Bagsværd, Denmark) duration:7 days(from admission (primary percutaneous coronary intervention) to discharge) the intervention:once-daily subcutaneous liraglutide 0.6 mg for 2 days, then gradually increase the dosage, once-daily subcutaneous liraglutide 1.2 mg for 2 days ,once-daily subcutaneous liraglutide 1.8 mg for 3 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>liraglutide placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>drug:liraglutide placebo (Novo Nordisk) duration:7 days(from admission (primary percutaneous coronary intervention) to discharge) the intervention:once-daily subcutaneous liraglutide placebo 0.6 mg for 2 days, then gradually increase the dosage, once-daily subcutaneous liraglutide placebo 1.2 mg for 2 days ,once-daily subcutaneous liraglutide placebo 1.8 mg for 3 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liraglutide (Novo Nordisk, Bagsværd, Denmark)</intervention_name>
    <description>once-daily subcutaneous liraglutide 0.6 mg for 2 days, then gradually increase the dosage, once-daily subcutaneous liraglutide 1.2 mg for 2 days ,once-daily subcutaneous liraglutide 1.8 mg for 3 days</description>
    <arm_group_label>liraglutide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liraglutide placebo (Novo Nordisk)</intervention_name>
    <description>once-daily subcutaneous liraglutide placebo 0.6 mg for 2 days, then gradually increase the dosage, once-daily subcutaneous liraglutide placebo 1.2 mg for 2 days ,once-daily subcutaneous liraglutide placebo 1.8 mg for 3 days</description>
    <arm_group_label>liraglutide placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients were eligible if they were 18 years or older and presented within 12 h from the
        onset of symptoms and signs of ST-segment elevation myocardial infarction to the
        catheterization laboratory.

        Exclusion Criteria:

        The patients were not considered for enrolment if they presented with unconsciousness,
        cardiogenic shock, hypoglycaemia, diabetic ketoacidosis, previous myocardial infarction,
        stent thrombosis, known renal insufficiency, or previous coronary artery bypass operation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yun Dai Chen, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>World Health Organization</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wei Ren Chen, M.D.</last_name>
    <phone>+8610-66939709</phone>
    <email>chen_weiren@sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei Ren Chen, M.D.</last_name>
      <phone>+8610-66939709</phone>
      <email>chen_weiren@sina.com</email>
    </contact>
    <investigator>
      <last_name>Yun Dai Chen, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H, Olvera-Alvarez I, Hale PM, Zdravkovic M, Bode B; LEAD-3 (Mono) Study Group. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2009 Feb 7;373(9662):473-81. doi: 10.1016/S0140-6736(08)61246-5. Epub 2008 Sep 24.</citation>
    <PMID>18819705</PMID>
  </reference>
  <reference>
    <citation>Lønborg J, Vejlstrup N, Kelbæk H, Bøtker HE, Kim WY, Mathiasen AB, Jørgensen E, Helqvist S, Saunamäki K, Clemmensen P, Holmvang L, Thuesen L, Krusell LR, Jensen JS, Køber L, Treiman M, Holst JJ, Engstrøm T. Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur Heart J. 2012 Jun;33(12):1491-9. doi: 10.1093/eurheartj/ehr309. Epub 2011 Sep 14.</citation>
    <PMID>21920963</PMID>
  </reference>
  <reference>
    <citation>Liu H, Dear AE, Knudsen LB, Simpson RW. A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules. J Endocrinol. 2009 Apr;201(1):59-66. doi: 10.1677/JOE-08-0468. Epub 2009 Jan 9.</citation>
    <PMID>19136619</PMID>
  </reference>
  <results_reference>
    <citation>Noyan-Ashraf MH, Momen MA, Ban K, Sadi AM, Zhou YQ, Riazi AM, Baggio LL, Henkelman RM, Husain M, Drucker DJ. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes. 2009 Apr;58(4):975-83. doi: 10.2337/db08-1193. Epub 2009 Jan 16.</citation>
    <PMID>19151200</PMID>
  </results_reference>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 27, 2013</study_first_submitted>
  <study_first_submitted_qc>December 3, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2013</study_first_posted>
  <last_update_submitted>February 4, 2016</last_update_submitted>
  <last_update_submitted_qc>February 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Chinese PLA General Hospital</investigator_affiliation>
    <investigator_full_name>Chen Wei Ren, MD</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <keyword>Reperfusion injury</keyword>
  <keyword>Liraglutide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Reperfusion Injury</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liraglutide</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
    <mesh_term>Glucagon</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

